Department of Pharmacy Practice, College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Pharmacy Practice and Science Department, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
Department of Pharmacy Practice, College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
J Infect Chemother. 2020 Jun;26(6):535-539. doi: 10.1016/j.jiac.2020.01.005. Epub 2020 Feb 17.
Lomefloxacin may be more likely than other fluoroquinolones to cause photosensitivity. However, the rate of photosensitivity is variable and a meta-analysis has yet to be performed. The aim of this meta-analysis is to compare the rate of photosensitivity between outpatients who received lomefloxacin and those who received other fluoroquinolones. PubMed, EMBASE, Cochrane Library databases and trial registries were searched for randomized controlled trials (RCTs) of outpatients through June 12, 2019. The study outcome was the rate of photosensitivity based on the intention-to-treat principle, estimated by risk difference (RD) as the primary analysis and Peto odds ratio (Peto OR) as the secondary analysis, with 95% confidence intervals (CIs) using random-effects models. Four RCTs (total of 2295 patients) were included in this meta-analysis. A statistically higher risk of photosensitivity was found with lomefloxacin than with other fluoroquinolones (RD, 3.4%; 95% CI, 0.7%-6.2%; P-value = 0.013; I = 10.9%). The odds of photosensitivity was also significantly higher with lomefloxacin (Peto OR, 5.81; 95% CI, 3.34 to 10.11; P-value <0.001; I = 0%). This meta-analysis of RCTs found significantly higher photosensitivity with lomefloxacin compared to other fluoroquinolones. Considering this finding and given its lack of additional efficacy compared to other fluoroquinolones, lomefloxacin as a fluoroquinolone option should potentially be reconsidered.
洛美沙星比其他氟喹诺酮类药物更有可能引起光过敏。然而,光过敏的发生率是可变的,尚未进行荟萃分析。本荟萃分析的目的是比较接受洛美沙星和其他氟喹诺酮类药物治疗的门诊患者的光过敏发生率。通过 2019 年 6 月 12 日检索 PubMed、EMBASE、Cochrane 图书馆数据库和试验登记处的随机对照试验(RCT)。研究结果是基于意向治疗原则的光过敏发生率,采用风险差异(RD)进行估计,主要分析为风险差异(RD),次要分析为 Peto 比值比(Peto OR),置信区间(CI)为 95%,采用随机效应模型。本荟萃分析纳入了 4 项 RCT(共 2295 例患者)。与其他氟喹诺酮类药物相比,洛美沙星发生光过敏的风险明显更高(RD,3.4%;95%CI,0.7%-6.2%;P 值=0.013;I=10.9%)。洛美沙星发生光过敏的几率也明显更高(Peto OR,5.81;95%CI,3.34 至 10.11;P 值<0.001;I=0%)。本 RCT 荟萃分析发现,与其他氟喹诺酮类药物相比,洛美沙星的光过敏发生率明显更高。考虑到这一发现,并且与其他氟喹诺酮类药物相比,洛美沙星没有额外的疗效,洛美沙星作为氟喹诺酮类药物的选择可能需要重新考虑。